Abstract
Although histopathological analysis of liver tissue is still the reference standard for the evaluation of disease progression in patients with chronic liver disease, a distinct change in clinical practice is occurring. The tendency to substitute histopathological analysis of liver biopsies with complex, surrogate 'noninvasive' measures of disease progression has grown to such a level that clarification and guidance on their use is needed. This Review provides an overview of the proposed noninvasive diagnostic methodologies and their possible integration with the standard invasive procedures used for the evaluation of disease progression (i.e. liver biopsy and the measurement of portal pressure). A concise analysis of what has been proposed for the differentiation of simple fatty liver from nonalcoholic steatohepatitis and its possible fibrogenic evolution is also included. In particular, the Review focuses on the methods easily available as part of daily clinical practice in hepatology—biochemical markers and transient elastography (i.e. liver stiffness measurement).
Key Points
-
Several noninvasive approaches—serum markers, transient elastography and imaging—have been proposed as a replacement for, or accompaniment to, histopathological analysis of liver biopsies for the assessment of liver fibrosis
-
All proposed noninvasive methodologies have sufficient-to-excellent diagnostic accuracy for the detection (or exclusion) of advanced fibrosis and cirrhosis, but none allow a step-wise follow-up of the fibrogenic evolution of chronic liver disease according to the existing histopathological staging systems; in addition, none of the currently available tests has a well-defined prognostic value, such as the prediction of decompensation or death
-
Due to 'spectrum bias' and the possible causes of discordance with the histopathological assessment, applying the different proposed cut-off values in clinical practice is currently hazardous
-
Combining two unrelated noninvasive tests (i.e. a biochemical test and liver stiffness measurement) might be useful for the initial assessment of fibrosis evolution in patients with chronic liver disease
-
Most noninvasive methods could be instrumental in staging advanced fibrosis from F3/F4 and beyond
-
A noninvasive approach to NAFLD would need to differentiate NASH from bland steatosis in addition to detecting clinically relevant fibrosis and monitoring disease progression
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 15–20
Abdel Aziz M et al. (2007) FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 102: 1–12
Regev A et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614–2618
Bedossa P et al. (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449–1457
Cadranel JF et al. (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 32: 477–481
Standish RA et al. (2006) An appraisal of the histopathological assessment of liver fibrosis. Gut 55: 569–578
Goodman ZD et al. (2007) Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 45: 886–894
Samonakis DN et al. (2007) Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 13: 1305–1311
Blasco A et al. (2006) Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43: 492–499
Burroughs AK et al. (2005) Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 50: 425–427
Rincon D et al. (2006) Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 101: 2269–2274
Senzolo M et al. (2006) The transjugular route: the key hole to the liver world. Dig Dis Sci 39: 105–116
Carrion JA et al. (2007) Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 132: 1746–1756
Nagula S et al. (2006) Histological–hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol 44: 111–117
Pinzani M et al. (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 (Suppl 1): S22–S36
Parkes J et al. (2006) Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 44: 462–474
Afdhal NH and Curry M (2007) Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol 46: 543–545
Poynard T et al (2004) Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50: 1344–1355
Calès P et al. (2005) A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42: 1373–1381
Rosenberg WM et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704–1713
Sebastiani G et al. (2004) Stepwise combination of algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 44: 686–693
Sebastiani G et al (2007) Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 13: 525–531
Leroy V et al. (2007) Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 46: 775–782
Lackner C et al. (2005) Comparison and validation of simple non-invasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41: 1376–1382
Lackner C et al. (2006) Non-invasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests. Hepatology 42: 378–379
Sandrin L et al. (2002) Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 49: 436–446
Castera L et al. (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128: 343–350
Carrion JA et al. (2006) Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 12: 1791–1798
Foucher J et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403–408
Gomez-Dominguez E et al. (2006) Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 24: 513–518
Ganne-Carrie N et al. (2006) Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 44: 1511–1517
de Ledinghen V et al. (2006) Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus co-infected patients. J Acquir Immune Defic Syndr 41: 175–179
Kim KM et al. (2007) Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 42: 382–388
Yoneda M et al. (2007) Transient elastography in patients with nonalcoholic fatty liver disease (NAFLD). Gut 56: 1330–1331
Ziol M et al. (2005) Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41: 48–54
Fraquelli M et al. (2007) Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56: 968–973
Corpechot C et al. (2006) Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 43: 1118–1124
Coco B et al. (2007) Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 14: 360–369
Arena U et al.: Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology, in press
Imbert-Bismut F et al. (2004) Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 42: 323–333
Vizzutti F et al. (2007) Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 45: 1290–1297
Foucher J et al. (2006) Diagnosis of cirrhosis by transient elastography (Fibroscan): a prospective study. Gut 55: 403–408
Kazemi F et al. (2006) Liver stiffness measurements selects patients with cirrhosis at risk of bearing large esophageal varices. J Hepatol 45: 230–235
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221–1231
Ratziu V et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898–1906
Angulo P et al. (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356–1362
Ratziu V et al. (2000) Liver fibrosis in overweight patients. Gastroenterology 118: 1117–1123
Dixon JB et al. (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91–100
Matteoni CA et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413–1419
Fassio E et al. (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820–826
Adams LA et al. (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42: 132–138
Albano E et al. (2005) Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54: 987–993
Bugianesi E et al. (2004) Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39: 179–187
Marchesini G et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923
Angulo P et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45: 846–854
Adams LA et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113–121
Suzuki A et al. (2005) Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 25: 779–786
Sakugawa H et al. (2005) Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 11: 255–259
Ratziu V et al. (2006) Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 6
Poynard T et al. (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 34
Wieckowska A et al. (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27–33
Bedogni G et al. (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33
Dunn W et al. (2006) Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 131: 1057–1063
Forns X et al. (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36: 986–992
Wai CT et al. (2003) A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518–526
Imbert-Bismut F et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069–1075
Koda M et al. (2007) FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 45: 297–306
Testa R et al. (2006) Non-invasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med 260: 142–150
Sud A et al. (2004) Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39: 1239–1247
Sterling RK et al. (2006) Development of a simple non-invasive index to predict significant fibrosis in patients with chronic hepatitis C. Hepatology 43: 1317–1325
Bonacini M et al. (1997) Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C infection. Am J Gastroenterol 92: 1302–1314
Pohl A et al. (2001) Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 96: 3142–3146
Sheth SG et al. (1998) AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 93: 44–48
Park GJH et al. (2000) Aspartate aminotransferase, alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 15: 386–390
Poynard T and Bedossa P (1997) Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 4: 199–208
Leroy V et al. (2004) Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99: 271–279
Kellher TB et al. (2005) Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43: 78–84
Adams LA et al. (2005) Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51: 1867–1873
Patel K et al. (2004) Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 41: 935–942
Acknowledgements
We are indebted to the reviewers of this article, who directed our attention to several relevant issues and controversies still present in this complex area of clinical investigation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
Supplementary Table 1 (DOC 32 kb)
Supplementary Information
Supplementary References (DOC 25 kb)
Rights and permissions
About this article
Cite this article
Pinzani, M., Vizzutti, F., Arena, U. et al. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Rev Gastroenterol Hepatol 5, 95–106 (2008). https://doi.org/10.1038/ncpgasthep1025
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1025
This article is cited by
-
Development of a Simple Noninvasive Model to Predict Significant Fibrosis in Patients with Chronic Hepatitis B: Combination of Ultrasound Elastography, Serum Biomarkers, and Individual Characteristics
Clinical and Translational Gastroenterology (2017)
-
A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C
Hepatology International (2017)
-
Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update
Hepatology International (2017)
-
Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients
Journal of Translational Medicine (2016)
-
Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging
EJNMMI Research (2015)